Toll Like Receptor 4 hToll or CD284 or TLR4 Pipeline Review, H1 2019
Summary
According to the recently published report 'Toll Like Receptor 4 Pipeline Review, H1 2019'; Toll Like Receptor 4 hToll or CD284 or TLR4 pipeline Target constitutes close to 37 molecules. Out of which approximately 28 molecules are developed by companies and remaining by the universities/institutes.
Toll Like Receptor 4 hToll or CD284 or TLR4 Tolllike receptor 4 is a protein encoded by the TLR4 gene. This receptor is mostly expressed in placenta, and in myelomonocytic subpopulation of the leukocytes. It is involved in LPSindependent inflammatory responses triggered by free fatty acids, such as palmitate, and Ni2+. It responses are triggered by Ni2+ require nonconserved. In complex with TLR6 promotes sterile inflammation in monocytes in response to oxidized lowdensity lipoprotein oxLDL.
The report 'Toll Like Receptor 4 Pipeline Review, H1 2019' outlays comprehensive information on the Toll Like Receptor 4 hToll or CD284 or TLR4 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type; that are being developed by Companies / Universities.
It also reviews key players involved in Toll Like Receptor 4 hToll or CD284 or TLR4 targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 8, 2, 12 and 4 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 7 and 2 molecules, respectively.
Report covers products from therapy areas Oncology, Gastrointestinal, Infectious Disease, Immunology, Cardiovascular, Central Nervous System, Genito Urinary System And Sex Hormones, Respiratory, Dermatology, Ear Nose Throat Disorders, Mouth and Dental Disorders, Musculoskeletal Disorders and Ophthalmology which include indications NonAlcoholic Steatohepatitis NASH, Autoimmune Hepatitis, Inflammation, Atherosclerosis, Dengue Fever, Kidney Fibrosis, Liver Fibrosis, Non Alcoholic Fatty Liver Disease NAFLD, Pain, Rheumatoid Arthritis, Sepsis, Solid Tumor, Acute Ischemic Stroke, Acute Liver Failure, Acute Lung Injury, Atopic Dermatitis Atopic Eczema, Autoimmune Disorders, Bacterial Sepsis, Breast Cancer, Chronic Liver Disease, Complicated IntraAbdominal Infections, Crohn's Disease Regional Enteritis, Cutaneous TCell Lymphoma, Diffuse Large BCell Lymphoma, Drug Addiction, Ebolavirus Infections Ebola Hemorrhagic Fever, Endotoxemia, Escherichia coli Infections, Follicular Lymphoma, Head And Neck Cancer Squamous Cell Carcinoma, Hearing Disorders, Hepatic Injury, Hypopharyngeal Cancer, Inflammatory Bowel Disease, Keratoconjunctivitis Sicca Dry Eye, Laryngeal Cancer, Low Back Pain, Lung Cancer, Marburgvirus Infections Marburg Hemorrhagic Fever, Melanoma, Merkel Cell Carcinoma, Metastatic Melanoma, Migraine, Multiple Sclerosis, Necrotizing Enterocolitis, Non Muscle Invasive Bladder Cancer NMIBC Superficial Bladder Cancer, Oral Cavity Mouth Cancer, Oropharyngeal Cancer, Osteoarthritis, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Pseudomonas aeruginosa Infections, Pulmonary Edema, Pulmonary Inflammation, Rosacea, Soft Tissue Sarcoma and Xerostomia.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
The report provides a snapshot of the global therapeutic landscape for Toll Like Receptor 4 hToll or CD284 or TLR4
The report reviews Toll Like Receptor 4 hToll or CD284 or TLR4 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources
The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, RD brief, licensing and collaboration details other developmental activities
The report reviews key players involved in Toll Like Receptor 4 hToll or CD284 or TLR4 targeted therapeutics and enlists all their major and minor projects
The report assesses Toll Like Receptor 4 hToll or CD284 or TLR4 targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type
The report summarizes all the dormant and discontinued pipeline projects
The report reviews latest news and deals related to Toll Like Receptor 4 hToll or CD284 or TLR4 targeted therapeutics
Reasons to buy
Gain strategically significant competitor information, analysis, and insights to formulate effective RD strategies
Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage
Identify and understand the targeted therapy areas and indications for Toll Like Receptor 4 hToll or CD284 or TLR4
Identify the use of drugs for target identification and drug repurposing
Identify potential new clients or partners in the target demographic
Develop strategic initiatives by understanding the focus areas of leading companies
Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
Devise corrective measures for pipeline projects by understanding Toll Like Receptor 4 hToll or CD284 or TLR4 development landscape
Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope